10-day vs 5-day decitabine

equivalence cannot be concluded – Authors' reply

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)e178
JournalThe Lancet Haematology
Volume6
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

decitabine

ASJC Scopus subject areas

  • Hematology

Cite this

10-day vs 5-day decitabine : equivalence cannot be concluded – Authors' reply. / Short, Nicholas J; Ravandi-Kashani, Farhad.

In: The Lancet Haematology, Vol. 6, No. 4, 01.04.2019, p. e178.

Research output: Contribution to journalLetter

@article{58edd921b0294bbc980d9ad727b78f8f,
title = "10-day vs 5-day decitabine: equivalence cannot be concluded – Authors' reply",
author = "Short, {Nicholas J} and Farhad Ravandi-Kashani",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/S2352-3026(19)30052-3",
language = "English (US)",
volume = "6",
pages = "e178",
journal = "The Lancet Haematology",
issn = "2352-3026",
publisher = "Lancet Publishing Group",
number = "4",

}

TY - JOUR

T1 - 10-day vs 5-day decitabine

T2 - equivalence cannot be concluded – Authors' reply

AU - Short, Nicholas J

AU - Ravandi-Kashani, Farhad

PY - 2019/4/1

Y1 - 2019/4/1

UR - http://www.scopus.com/inward/record.url?scp=85063288617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063288617&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(19)30052-3

DO - 10.1016/S2352-3026(19)30052-3

M3 - Letter

VL - 6

SP - e178

JO - The Lancet Haematology

JF - The Lancet Haematology

SN - 2352-3026

IS - 4

ER -